An interventional study of Paradise™ (PRDS-001) Renal Denervation Ultrasound System and Renal Angiogram in Hypertension, Vascular Diseases and Cardiovascular Diseases, sponsored by Otsuka Medical Devices Co., Ltd. Japan. Active, not recruiting at 51 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Otsuka Medical Devices Co., Ltd. Japan (part of Otsuka Holdings Co., Ltd.) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 142 studies in Hypertension with a site in Japan — 11 open to participants now, 17 under way, 8 of them phase 3. Hypertension · Japan.
Among the 142 studies in Hypertension with a site in Japan, this one is the 80th largest by planned enrollment of the 125 interventional ones that give a count, is one of 3 that started in 2022, is one of 12 with no phase, reaches primary completion later than 1 of the 16 other live ones, and was the 119th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →11 of the 142 studies in Hypertension with a site in Japan are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Japan, United States, Argentina and 1 more country
Ages 18+
Innovent Biologics (Suzhou) Co. Ltd. · Sites in Japan
Ages 18–75
Novartis Pharmaceuticals · Sites in Japan
Ages 18–60 · Healthy volunteers
Novartis Pharmaceuticals · Sites in Japan, United States, Singapore
Ages 18+
Alnylam Pharmaceuticals · Sites in Japan, United States, Argentina and 32 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
142 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 17 · Phase 3 50 · Phase 4 41
First in 2000; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 154 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 237 across the 125 interventional studies, 1,452 across the 17 observational. Of the 105 that completed or were terminated, 48 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 142 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Medical Devices Co., Ltd. Japan, one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Medical Devices Co., Ltd. Japan is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Otsuka Holdings Co., Ltd. has 9 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
9 of the studies in Hypertension with a site in Japan that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06948422Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | 2027-09 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
| NCT06952530Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | 2027-09 |
| NCT05326230Otsuka Medical Devices Co., Ltd. JapanA Clinical Study of the Paradise™ Renal Denervation System in Patients With Hypertension (RADIANCE-HTN DUO) | 2026-12 |
| NCT07644364Novartis PharmaceuticalsHJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension | 2026-12-25 |
Add all 9 to your calendar (.ics) → With an account.
Among the 142 studies in Hypertension with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To compare the antihypertensive effect of renal denervation with the Paradise™ system with that of a sham procedure in hypertensive patients receiving two antihypertensive drugs at the time of consent, and treated with a duo combination antihypertensive pill.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Patients with any of the following central laboratory tests at screening
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Renal Angiogram and Renal Denervation (PRDS-001- Paradise™ System)
Device: Paradise™ (PRDS-001) Renal Denervation Ultrasound System
Renal Angiogram
Device: Renal Angiogram
Following renal angiogram according to standard procedures, subjects remain blinded and are randomized to treatment with renal denervation or sham control
Also known as: Renal Angiogram/Renal Denervation
Following renal angiogram according to standard procedures, subjects remain blinded and renal angiogram is considered the sham procedure
Mean change in 24-hour systolic ABPM
Time frame: From baseline to 3 months post-procedure
Mean change in 24-hour systolic ABPM
Time frame: from baseline to 6 months post-procedure
Mean change in daytime/nighttime /24-hour ABPM (systolic/diastolic) (excluding primary and important secondary endpoints)
Time frame: From baseline to 3, 6, 12 months post-procedure
Change in mean sitting office blood pressure (systolic/diastolic)
Time frame: From baseline to 1, 2, 3, 4, 5, 6, 9, 12, 24, 36 months post-procedure
Change in mean home blood pressure (systolic/diastolic)
Time frame: From baseline to 1, 2, 3, 4, 5, 6, 9, 12, 24, 36 months post-procedure
Percentage of subjects with a mean decrease in daytime/nighttime/24-hour systolic ABPM of ≥5 mmHg, ≥10 mmHg, and ≥15 mmHg
Time frame: 3, 6, and 12months post-procedure
Percentage of subjects who required a change in antihypertensive medication
Time frame: at any time up to 12 months after the procedure
Percentage of subjects who achieved blood pressure control without any change in antihypertensive medication
Time frame: 3, 6, 12 months after the procedure
Percentage of subjects whose blood pressure was controlled by changing antihypertensive medication
Time frame: 3, 6, 12 months after the procedure
Change in mean pulse pressure (difference between systolic and diastolic blood pressure) in the office, home, ABPM
Time frame: 3, 6, 12 months after the procedure
Change in mean heart rate in the office, home, ABPM
Time frame: 3, 6, 12 months after the procedure
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2022 (actual). Primary completion is estimated for Dec 2026, 53 months after the start.
Of 95 industry-sponsored interventional studies with no phase under Hypertension, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 53 months is above that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Otsuka Medical Devices Co., Ltd. Japan →